These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19710077)

  • 41. Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study.
    Nishijima T; Tsuchiya K; Tanaka N; Joya A; Hamada Y; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Oka S; Gatanaga H
    J Antimicrob Chemother; 2014 Dec; 69(12):3320-8. PubMed ID: 25151207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.
    Ferraris L; Viganò O; Peri A; Tarkowski M; Milani G; Bonora S; Adorni F; Gervasoni C; Clementi E; Di Perri G; Galli M; Riva A
    J Antimicrob Chemother; 2012 Sep; 67(9):2236-42. PubMed ID: 22661571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.
    Vanhove T; de Jonge H; de Loor H; Annaert P; Diczfalusy U; Kuypers DR
    Br J Clin Pharmacol; 2016 Dec; 82(6):1539-1549. PubMed ID: 27501475
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
    Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
    J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.
    Mallolas J; Sarasa M; Nomdedeu M; Soriano A; López-Púa Y; Blanco JL; Martínez E; Gatell JM
    HIV Med; 2007 Mar; 8(2):131-4. PubMed ID: 17352770
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting.
    Haberl A; Moesch M; Nisius G; Stephan C; Bickel M; Khaykin P; Kurowski M; Brodt R; von Hentig N
    Eur J Clin Pharmacol; 2010 Apr; 66(4):375-81. PubMed ID: 20033681
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.
    Carey D; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray JE; Boyd MA; Emery S; Cooper DA
    J Acquir Immune Defic Syndr; 2012 Jun; 60(2):143-9. PubMed ID: 22421745
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D;
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.
    Iwamoto M; Wenning LA; Mistry GC; Petry AS; Liou SY; Ghosh K; Breidinger S; Azrolan N; Gutierrez MJ; Bridson WE; Stone JA; Gottesdiener KM; Wagner JA
    Clin Infect Dis; 2008 Jul; 47(1):137-40. PubMed ID: 18513146
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.
    Shin J; Pauly DF; Pacanowski MA; Langaee T; Frye RF; Johnson JA
    Pharmacotherapy; 2011 Oct; 31(10):942-50. PubMed ID: 21950641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers.
    Krishna G; Moton A; Ma L; Martinho M; Seiberling M; McLeod J
    J Acquir Immune Defic Syndr; 2009 Aug; 51(4):437-44. PubMed ID: 19623694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
    Karlström O; Josephson F; Sönnerborg A
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):417-22. PubMed ID: 17159658
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats.
    Fukushima K; Haraya K; Terasaka S; Ito Y; Sugioka N; Takada K
    Biol Pharm Bull; 2008 Jun; 31(6):1209-14. PubMed ID: 18520056
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
    von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation.
    Woodahl EL; Hingorani SR; Wang J; Guthrie KA; McDonald GB; Batchelder A; Li M; Schoch HG; McCune JS
    Pharmacogenomics J; 2008 Aug; 8(4):248-55. PubMed ID: 17700595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors.
    Wang J; Zeevi A; McCurry K; Schuetz E; Zheng H; Iacono A; McDade K; Zaldonis D; Webber S; Watanabe RM; Burckart GJ
    Transpl Immunol; 2006 Jan; 15(3):235-40. PubMed ID: 16431292
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Cytochrome P450 3A5 Non-Expressor Kidney Allograft as a Risk Factor for Calcineurin Inhibitor Nephrotoxicity.
    Udomkarnjananun S; Townamchai N; Chariyavilaskul P; Iampenkhae K; Pongpirul K; Sirichindakul B; Panumatrassamee K; Vanichanan J; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K
    Am J Nephrol; 2018; 47(3):182-190. PubMed ID: 29539600
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
    Abel S; Russell D; Taylor-Worth RJ; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):27-37. PubMed ID: 18333863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.